NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease
08 juil. 2021 02h00 HE
|
NMD Pharma
PRESS RELEASE NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease The international observational study will be conducted in collaboration with Aarhus University and...
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670
30 juin 2021 07h00 HE
|
NMD Pharma
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670 Aarhus, Denmark, 30 June 2021 – NMD Pharma A/S, a biotech company leading in the development...
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670
30 juin 2021 02h00 HE
|
NMD Pharma
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670 Aarhus, Denmark, 30 June 2021 – NMD Pharma A/S, a biotech company leading in the development...
NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults
01 juin 2021 07h00 HE
|
NMD Pharma
PRESS RELEASE NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults Aarhus, Denmark, 1 June 2021 – NMD Pharma A/S,...
NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults
01 juin 2021 02h00 HE
|
NMD Pharma
PRESS RELEASE NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults Aarhus, Denmark, 1 June 2021 – NMD Pharma A/S,...
NMD Pharma Moves Corporate Headquarters to INCUBA to Support Future Growth
30 nov. 2020 01h00 HE
|
NMD Pharma
NMD Pharma Moves Corporate Headquarters to INCUBA to Support Future Growth Aarhus, Denmark, 30 November 2020 – NMD Pharma A/S, a biotech company leading in the development of novel therapeutics for...
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
06 oct. 2020 07h00 HE
|
NMD Pharma
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 6 October 2020 – NMD Pharma A/S, a biotech company...
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
06 oct. 2020 01h00 HE
|
NMD Pharma
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 6 October 2020 – NMD Pharma A/S, a biotech company...
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
14 juil. 2020 07h00 HE
|
NMD Pharma
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
14 juil. 2020 02h00 HE
|
NMD Pharma
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...